Navigation Links
Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors
Date:11/24/2008

LA JOLLA, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically targeted medications, today announced that Mr. Lynn Swann has been appointed to the Company's Board of Directors.

Mr. Swann is president of Swann, Inc., a consulting firm specializing in marketing and communications and managing director of Diamond Edge Capital Partners, LLC, a New York-based finance company.

Mr. Swann currently serves on the Board of Directors of H.J. Heinz Company, Hershey Entertainment and Resorts Company and Harrah's Entertainment, Inc. He was also chairman of the President's Council on Physical Fitness and Sports from 2002-2005. A former all-pro wide receiver for the Pittsburgh Steelers and 2001 Hall of Famer, he spent twenty-nine years with ABC Sports as a sports analyst and broadcaster before retiring in 2006.

Active in community affairs, Mr. Swann is national spokesman and former board president of Big Brothers and Sisters of America and former director of the Pittsburgh Ballet Theatre. Mr. Swann holds a B.A. degree in public relations from the University of Southern California.

Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals, Inc., commented, "Over the course of his life in the public eye, Mr. Swann has proven himself to be a great leader both on and off the field. Transdel is extremely fortunate to strengthen its Board of Directors by adding an individual as experienced and accomplished as Mr. Swann. He is a tremendous addition to the Company's Board especially given his extensive and diverse business background and business affiliations. We are delighted to welcome him to the team and look forward to his contributions in growing Transdel and expanding the Company's business opportunities."

Mr. Swann added: "I am pleased and honored to be joining the Board of Directors of Transdel Pharmaceuticals and look forward to contributing to the company's future success. Transdel's transdermal delivery platform technology is truly impressive. Given the growth of sports medicine, I am particularly excited about the company's lead drug, Ketotransdel(TM), its topical NSAID cream formulation for pain management and the unmet medical need that it will potentially fulfill."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical company developing non-invasive, topically delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

     Contact:
     John Lomoro, CFO
     Transdel Pharmaceuticals, Inc.
     858-457-5300
     E-mail: johnl@transdelpharma.com

     Or

     The Investor Relations Group
     Investor Relations:
     Rachel Colgate / Michael Crawford
     212-825-3210
     or
     Media Relations
     Laura Colontrelle / Janet Vasquez
     212-825-3210

'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
6. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
10. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
11. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: